Emergent BioSolutions Inc.
EBS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.00 | 0.01 | -0.36 |
| FCF Yield | 7.07% | -209.88% | -25.33% | 4.13% |
| EV / EBITDA | 20.29 | -18.54 | 86.30 | 5.14 |
| Quality | ||||
| ROIC | -11.79% | -47.65% | -5.68% | 9.44% |
| Gross Margin | 35.97% | 34.31% | 42.33% | 44.72% |
| Cash Conversion Ratio | -0.31 | 0.27 | 0.16 | 1.39 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.25% | -16.05% | -10.85% | 17.05% |
| Free Cash Flow Growth | 113.88% | -72.05% | -255.98% | -75.67% |
| Safety | ||||
| Net Debt / EBITDA | 10.80 | -15.93 | 48.61 | 0.53 |
| Interest Coverage | -1.53 | -8.26 | -4.56 | 9.90 |
| Efficiency | ||||
| Inventory Turnover | 2.14 | 2.10 | 1.83 | 2.79 |
| Cash Conversion Cycle | 191.03 | 181.19 | 192.62 | 140.01 |